Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway

Fig. 4

Effects of RZM and Met on tumor growth in vivo. a Tumor growth curves were analyzed for RZM-treated, Met-treated and the control group. (*P < 0.05, **P < 0.01 versus the control group). b, c Nude mice were sacrificed after 4 weeks and the tumors in each group were exhibited. d, e The mean volume and weight of xenograft tumors from indicated treatment were analyzed (*P < 0.05, **P < 0.01 versus the control group). f Relative protein expressions of AMPK, p-AMPK and p21 in RZM-treated, Met-treated and the control group (n = 3, each group)

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us